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Cell (CSC) Activity
Rosa Sánchez-Alvarez 1†, Ernestina Marianna De Francesco 2,3†, Marco Fiorillo 2,
Federica Sotgia 2* and Michael P. Lisanti 2*
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Elevated mitochondrial biogenesis and metabolism represent key features of breast
cancer stem cells (CSCs), whose propagation is conducive to disease onset and
progression. Therefore, interfering with mitochondria biology and function may be
regarded as a useful approach to eradicate CSCs. Here, we used the breast cancer
cell line MCF7 as a model system to interrogate how mitochondrial fission contributes
to the development of mitochondrial dysfunction toward the inhibition of metabolic flux
and stemness. We generated an isogenic MCF7 cell line transduced with Mitochondrial
Fission Factor (MCF7-MFF), which is primarily involved in mitochondrial fission. We
evaluated the biochemical, molecular and functional properties of MCF7-MFF cells, as
compared to control MCF7 cells transduced with the empty vector (MCF7-Control). We
observed that MFF over-expression reduces both mitochondrial mass and activity, as
evaluated using the mitochondrial probes MitroTracker Red and MitoTracker Orange,
respectively. The analysis of metabolic flux using the Seahorse XFe96 revealed the
inhibition of OXPHOS and glycolysis in MCF7-MFF cells, suggesting that increased
mitochondrial fission may impair the biochemical properties of these organelles. Notably,
CSCs activity, assessed by 3D-tumorsphere assays, was reduced in MCF7-MFF cells.
A similar trend was observed for the activity of ALDH, a well-established marker of
stemness. We conclude that enhanced mitochondrial fission may compromise CSCs
propagation, through the impairment of mitochondrial function, possibly leading to a
quiescent cell phenotype. Unbiased proteomic analysis revealed that proteins involved in
mitochondrial dysfunction, oxidative stress-response, fatty acid metabolism and hypoxia
signaling are among the most highly up-regulated in MCF7-MFF cells. Of note, integrated
analysis of top regulatory networks obtained from unbiased proteomics in MCF7-MFF
cells predicts that this cell phenotype activates signaling systems and effectors involved
in the inhibition of cell survival and adhesion, together with the activation of specific breast
cancer cell death programs. Overall, our study shows that unbalanced and abnormal
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activation of mitochondrial fission may drive the impairment of mitochondrial metabolic
function, leading to inhibition of CSC propagation, and the activation of quiescence
programs. Exploiting the potential of mitochondria to control pivotal events in tumor
biology may, therefore, represent a useful tool to prevent disease progression.
Keywords: mitochondrial fission factor, CSCs, mitochondrial metabolism, breast cancer, mitochondrial dynamics,
oxidative metabolism, metabo-stemness, mitochondrial mass
INTRODUCTION
Mitochondrial function is essential for supplying energy to
fuel cancer cell growth and metastatic dissemination (1).
Furthermore, enhanced mitochondrial metabolism has emerged
as one of the novel features of cancer stem cells (CSCs), which
exhibit tumorigenic and self-renewal properties, carry metastatic
potential and provide resistance to anti-cancer therapies (2–4). In
this regard, cancer cells biologically recapitulate certain stemness
features, including anchorage-independent growth and higher
tumor-initiating capacity, as well as increased mitochondrial
mass, biogenesis and protein translation, across multiple tumor
types (5). These observations, which clearly suggest a key role
for mitochondria in CSC maintenance and propagation, are
corroborated by the evidence that mitochondrial metabolic
function and OXPHOS are augmented in cancer cells with
stemness features, as compared to the non-stem cancer cell
sub-population (6, 7). As a consequence of these findings, the
ability of several classes of mitochondria-interfering agents to
inhibit CSC dissemination has been explored, as reviewed in De
Francesco et al. (8). In this regard, several antibiotics that impair
mitochondrial protein translation, as a side effect, have been
shown to be effective in depleting the CSC population in vitro, as
well as in clinical studies (9–13). As such, a deeper understanding
of mitochondrial biology in cancer would pave the way toward
the identification of targeted therapeutics, aimed at selectively
halting and eradicating CSCs.
Adequate mitochondrial function also depends on the
intrinsic mechanical changes in the dynamic structure and
architecture of these organelles (14, 15). For instance, changes
in mitochondrial size and shape, as well as localization, are
critical for the homeostasis of the energetic machinery. The main
macro-mechanical events regulating mitochondrial architecture
are represented by cycles of mitochondrial fusion and fission
(fragmentation), that together constitute a mitochondrial
network (16, 17). Given their important role in maintaining
mitochondria homeostasis, fusion and fission are tightly
regulated processes, whose de-regulation is associated with
metabolic dysfunction, that may precede the establishment
of pathological phenotypes (14, 17). In cancer, the elevated
nutrient demands of proliferating cells are mainly fulfilled by
drastic changes in energetic metabolism, largely supported by
mitochondria, whose changes in function and shape are pivotal
to tumor growth (1). Indeed, several oncogenic signals have
been shown to influence the number of mitochondria, which
is dependent on fusion-fission dynamics (15, 16, 18). Likewise,
aberrant mitochondrial fission results in massive mitochondrial
fragmentation, resulting in inhibition of oxidative metabolism
and depletion of ATP (19). Mitochondrial Fission Factor (MFF)
is an integral membrane protein of the outer mitochondrial
membrane that serves as the main molecular mediator regulating
mitochondria fragmentation (20). During fission, the cytosolic
protein Drp1 is recruited to the mitochondrial surface via MFF
and the proteins Fis1 (mitochondrial fission protein 1), MiD49
and MiD51 (mitochondrial dynamics proteins of 49 and 51 kDa,
respectively) (21–23). Oligomeric Drp1 complexes are, thereafter,
assembled into specific structures named puncta, which wrap
around mitochondrial tubules, forcing them toward the fission
reaction (24). Several studies have demonstrated that increased
MFF expression is required for successive mitochondrial fission
and is associated with disease states (25). Nevertheless, the role
of MFF in regulating mitochondrial dynamics in breast cancer
has not been thoroughly elucidated.
Herein, we provide evidence that aberrant MFF expression
in breast cancer cells drastically inhibits mitochondrial mass
and function, associated with a reduction of mitochondrial
oxidative metabolism and ATP depletion. Proteomic profiling
of MFF-overexpressing breast cancer cells reveals a phenotype
associated with the inhibition of mitochondrial metabolism
and a quiescent cell state. Biologically, MFF-overexpressing
breast cancer cells exhibit impaired 3Dmammosphere formation
capacity, suggesting that the manipulation of mitochondrial
structure and dynamics may represent a useful tool to control
stemness traits in breast cancer.
MATERIALS AND METHODS
Cell Culture
MCF7 human breast cancer cells were purchased from ATCC.
Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 10% heat-inactivated fetal bovine
serum, 100 units/mL of penicillin, 100µg/mL of streptomycin
and 2mM Glutamax (ThermoScientific), in a 37◦C humidified
atmosphere containing 5% CO2, unless otherwise noted.
Lentiviral Gene Transduction
Lentiviral plasmids, packaging cells and reagents were from
Genecopoeia. Forty-eight hours after seeding, 293Ta packaging
cells were transfected with lentiviral vectors encoding the
mitochondrial fission factor (MFF, EX-Z4766-Lv-105), or empty
vector (EV, EX-NEG-Lv105), using the Lenti-PacTM HIV
Expression Packaging Kit, according to the manufacturer’s
instructions. Two days post-transfection, lentivirus-containing
culture mediumwas passed through a 0.45µmfilter and added to
the target cells (MCF7 cells) in the presence of 5µg/ml polybrene.
TransducedMCF7 cells were selected with 2.5µg/ml puromycin.
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FIGURE 1 | Mitochondrial fission factor (MFF) decreases mitochondrial activity and mass. (A) Evaluation of MFF overexpression. MCF7 cells, stably transduced with a
lentiviral vector encoding for mitochondrial fission factor (MCF-MFF) or the empty-vector (MCF-7 Control), were subjected to protein extraction and immunoblotted for
MFF. β-actin is shown as equal loading control. (B,C) MFF overexpression decreases mitochondrial activity and mass. Stably transduced MCF7 cells harboring MFF
(MCF-MFF) and the respective empty-vector (MCF-7 Control) were seeded for 24 h and then mitochondrial activity and mitochondrial mass were quantitated by FACS
analysis using the probes MitoTracker Orange (B) and MitoTracker Deep-Red (C). At least four replicates were performed in each experiment. Results are the average
of the mean of three independent experiments and are expressed as percentages normalized to the control ± SEM. ***p < 0.001.
Western Blotting
Western blotting of stably transduced MCF7 cells was used to
evaluate the efficiency of transduction. Briefly, 70–80% confluent
stably-transducedMCF7 cells (harboringMFF and the respective
Ex-Negative control) were harvested in lysis buffer (10mM
Tris pH 7.5, 150mM NaCl, 1% Triton X-100, and 60mM n-
octyl-glucoside), containing protease (Roche) and phosphatase
inhibitors (Sigma) and kept at 4◦C for 40min with rotation.
Lysates were cleared by centrifugation for 10min at 10, 000 × g
and supernatants were collected. Equal amounts of protein lysate,
as determined by using the BCA protein assay kit (Pierce), were
diluted in SDS sample buffer and dry-boiled for 5min, prior to
separation by SDS-PAGE using 4–20% acrylamide gels (Biorad).
Samples were then blotted onto nitrocellulose membranes
(Biorad), blocked in 5% milk in TBS-Tween 20 (P9416, Sigma)
for 1 h and probed with antibodies directed against MFF
(Abcam), or β-actin (Sigma), which was used as loading control.
Bound antibodies were detected using a horseradish peroxidase-
conjugated secondary antibody (ab6789 and ab6721, Abcam)
and the signal was visualized using Supersignal West Pico
chemiluminescent substrate (ThermoScientific).
Mitochondrial Staining
Mitochondrial activity was assessed using the fluorescent
probe MitoTracker Orange (CM-H2TMRos-reduced form)
(ThermoFisher), whose accumulation in mitochondria is
dependent upon membrane potential. Mitochondrial mass was
determined using the fluorescent probe MitoTracker Deep-Red
(ThermoFisher), which localizes to mitochondria regardless of
mitochondrial membrane potential. Stably transduced MCF7
cells (harboring MFF or the Ex-Negative Control) were seeded
for 48 h. After 48 h, the cells were incubated with pre-warmed
MitoTracker staining solution (diluted in DMEM without
serum to a final concentration of 10 nM) for 30min at 37◦C.
All subsequent steps were performed in the dark. Cells were
washed in PBS, harvested, and re-suspended in 300 µL of
PBS/Ca2+Mg2+. Cells were then analyzed by flow cytometry
using Fortessa (BD Bioscience). Data analysis was performed
using FlowJo software. Results are the average of the mean of
three independent experiments, were normalized to the control
(Ex-Neg) and are expressed as percentages of mean fluorescence
intensity. At least 4 biological replicates were performed in
each experiment.
Seahorse XFe96 Metabolic Flux Analysis
Real time oxygen consumption rates (OCRs) and Extracellular
acidification rates (ECARs) were determined for stably
transduced MCF7 cells using the Seahorse Extracellular
Flux (XFe96) analyzer (Seahorse Bioscience, MA, USA). Briefly,
10,000 cells per well were seeded into XFe96 well cell culture
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FIGURE 2 | Mitochondrial fission factor (MFF) reduces mitochondrial respiration. The metabolic profile of stably transduced MCF7 cells harboring MFF (MCF-MFF)
and the respective empty-vector (MCF-7 Control) was examined using the Seahorse XFe96 analyzer. (A) Oxygen consumption rate (OCR) is significantly reduced in
cells transduced with MFF as compared to control cells. (B–F) Significant reductions in respiration (basal and maximal), proton leak, ATP levels and non-mitochondrial
derived OCR were observed in MCF7 cells transduced with MFF as compared to the control cells. At least six replicates were performed in each experiment. Results
are the average of the mean of three independent experiments and are expressed as percentages normalized to the control ± SEM. *p < 0.05, **p < 0.01.
plates and incubated overnight with complete medium to allow
attachment. After 24 h of incubation, cells were washed in either
pre-warmed XF assay media containing 2mM glutamine, pH 7.4
for ECAR measurements or in XF assay media supplemented
with 10mM glucose, 1mM Pyruvate, 2mM L-glutamine and
adjusted at 7.4 pH for OCR measurements. Cells were then
maintained in 175 µL/well of XF assay media at 37◦C, in a
non-CO2 incubator for 1 h. During the incubation time, 25 µL of
80mM glucose, 9µM oligomycin, and 1M 2-deoxyglucose were
loaded for ECAR measurement or 10µM oligomycin, 9µM
FCCP, 10µM rotenone, 10µM antimycin A were loaded for
OCR measurements, in XF assay media into the injection ports
in the XFe96 sensor cartridge. Measurements were normalized
by protein content, determined by SRB. Data sets were analyzed
by employing XFe96 software and GraphPad Prism software,
using Student’s t-test calculations. Results are the average of
the mean of three independent experiments normalized to the
control and are expressed as percentages of mpH/min/SRB for
ECAR or pmol/min/SRB for OCR measurements. At least six
biological replicates were performed in each experiment.
3D Mammosphere Culture
A single cell suspension of stably transduced MCF7 cells was
prepared using enzymatic (1x Trypsin-EDTA, Sigma Aldrich),
and manual disaggregation (25 gauge needle) as previously
described (26). Cells were plated at a density of 500 cells/cm2 in
DMEM-F12 phenol free supplemented with B27, 20,ng/ml EGF
and 1% Pen/Strep in non-adherent conditions, in culture dishes
coated with 2-hydroxyethylmethacrylate (poly-HEMA, Sigma-
Aldrich). Cells were grown for 5 days and maintained in a
humidified incubator at 37◦C. After 5 days in culture, spheres
> 50µm were counted using an eyepiece graticule. Results
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FIGURE 3 | Mitochondrial fission factor (MFF) reduces glycolysis. The metabolic profile of stably transduced MCF7 cells harboring MFF (MCF-MFF) and the respective
empty-vector (MCF-7 Control) was examined using the Seahorse XFe96 analyzer. (A) Extracellular acidification rate (ECAR) is significantly reduced in cells transduced
with MFF as compared to control cells. (B,C) Significant reduction in glycolysis and glycolytic capacity were observed in MCF7 cells transduced with MFF as
compared to control cells, without significant changes in glycolytic reserve (D), non-glycolytic acidification (E), and glycolytic reserve capacity (F). At least six
replicates were performed in each experiment. Results are the average of the mean of three independent experiments and are expressed as percentages normalized
to the control ± SEM. *p < 0.05, ***p < 0.001.
are the average of the mean of three independent experiments
normalized to the control (Ex-Neg) and are expressed as
percentage of cells plated which formed spheres. Three biological
replicates were performed in each experiment.
Aldefluor Assay
ALDH activity was assessed in stably transduced MCF7 cells,
which were seeded in monolayer for 48 h. The ALDEFLUOR
kit (StemCell Technologies) was used to isolate the population
with high ALDH enzymatic activity by flow cytometry (Fortessa,
BD Bioscience). Briefly, cells were harvested and incubated in
1ml of ALDEFLUOR assay buffer containing ALDH substrate
(5 µl/ml) for 40min at 37◦C. In each experiment, a sample
of cells was stained under identical conditions with 30mM of
diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor,
as a negative control. The ALDH-positive population was
established, according to the manufacturer’s instructions and was
evaluated using 30,000 cells.
Proteomics and Ingenuity Pathway
Analysis (IPA)
Samples were submitted to the CRUK Proteomics Core Facility,
for label-free proteomic analysis. Proteomics and statistical
analyses were carried out on a fee-for-service basis by Smith
and his colleagues, at the Proteomics Core Facility at the Cancer
Research UK Manchester Institute, University of Manchester.
Briefly, stably transduced MCF7 cells were cultured in complete
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FIGURE 4 | Mitochondrial fission factor (MFF) inhibits 3D-spheroid formation and ALDH activity. (A) Evaluation of mammosphere formation efficiency (MFE) in stably
transduced MCF7 cells harboring the mitochondrial fission factor (MCF7-MFF) and the respective empty-vector (MCF-7 Control), which were seeded on
low-attachment plates for 5 days. Under these conditions, MCF7-MFF cells show a reduction by 45% in the mammosphere forming capacity as compared to
MCF7-Control cells. (B) Evaluation of ALDEFLUOR activity, an independent marker of CSCs in MCF7 cells harboring MFF (MCF7-MFF) and the respective empty
vector control (MCF-Control). Each sample was normalized using diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as negative control. (C) The tracing of
representative samples is shown. Results are the average of the mean of three independent experiments performed in triplicate and are expressed as percentages
normalized to the control ± SEM. **p < 0.01.
media at a density of 1.8 × 106 in 10 cm dish. The day after
plating, the media was changed to DMEM with 10% NuSerum,
Pen-Strep and Glutamax. After 24 h, 70–75% of confluence
was reached. Then, cells were washed twice with PBS and
RIPA lysis buffer was added without protease inhibitors to
detach the cells. The lysates were collected into pre-cooled
tubes and kept on ice for 10min. After centrifugation, the
supernatants were collected and the samples were flash-frozen
using liquid nitrogen. Previously, a small aliquot was removed
for protein quantification. Samples were kept at −80◦C until
further analysis. Samples were subjected to proteomics following
a protocol previously described (27). Briefly, cell lysates were
prepared for trypsin digestion by sequential reduction of disulfide
bonds with TCEP and alkylation with MMTS. Then, the
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TABLE 1 | Significant changes in protein levels associated with mitochondrial
biogenesis in MCF7 cells over-expressing mitochondrial fission factor (MFF).
Symbol Gene name Fold change
Mitochondrial biogenesis
MFN2 Mitofusin 2 −31.184
MTERF1 Mitochondrial transcription termination factor 1 −5.38
MTFR1 Mitochondrial fission regulator 1 −9.616
TFAM Transcription factor A, mitochondrial 1.519
TIMM50 Translocase of inner mitochondrial membrane 50 −83.102
TIMM10B Translocase of inner mitochondrial membrane 10
homolog B (yeast)
−157.576
TIMM23B Translocase of inner mitochondrial membrane 23
homolog B
1.56
TIMM8B Translocase of inner mitochondrial membrane 8
homolog B
−5.662
TIMM13 Translocase of inner mitochondrial membrane 13 −2.266
TOMM34 Translocase of outer mitochondrial membrane 34 −5.272
TSFM Ts translation elongation factor, mitochondrial 1.635
YY1 YY1 transcription factor Infinity
SIRT6 Sirtuin 6 −8.746
Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-
regulated proteins; Green: down-regulated proteins. Proteomics was performed as
described in Materials and Methods. Statistical analyses were performed using ANOVA
and 1.5-fold-changes in proteins with a p < 0.05 were considered. Dataset containing
proteins with significant altered expression profile were imported into the Ingenuity
Pathway Analyses (IPA) software, which groups the differentially expressed proteins into
known functions and pathways.
peptides were extracted and prepared for LC-MS/MS. All LC-
MS/MS analyses were performed on an LTQ Orbitrap XL mass
spectrometer (ThermoScientific) coupled to an Ultimate 3000
RSLCnano system (ThermoScientific). Xcalibur raw data files
acquired on the LTQ-Orbitrap XL were directly imported into
Progenesis LCMS software (Waters Corp.) for peak detection
and alignment. Data were analyzed using the Mascot search
engine. Five replicates were analyzed for each sample type
(N = 5). Statistical analyses were performed using ANOVA
and a 1.5-fold-change in protein levels, with a p < 0.05 were
considered significant. The molecular function and biological
pathways of the differentially expressed proteins were performed
by the unbiased interrogation and analysis of proteomic data sets
using IPA (Ingenuity systems, http://www.ingenuity.com). IPA
assists with data interpretation, via the grouping of differentially
expressed genes or proteins into known functions and pathways.
Pathways with a z score of > +2 were considered as significantly
activated, while pathways with a z score of <-2 were considered
as significantly inhibited.
Statistical Analysis
Data is represented as the mean ± standard error of the
mean (SEM), taken over ≥3 independent experiments, with
≥3 technical replicates per experiment, unless stated otherwise.
Statistical significance was measured, using the Student t-test. A
p < 0.05 was considered statistically significant.
TABLE 2 | Significant changes in protein levels associated with oxidative
phosphorylation in MCF7 cells over-expressing the mitochondrial fission factor
(MFF).
Symbol Gene name Fold change
Oxidative phosphorylation
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1
complex, alpha subunit 1, cardiac muscle
9.846
ATP5B ATP synthase, H+ transporting, mitochondrial F1
complex, beta polypeptide
1781.432
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1
complex, gamma polypeptide 1
−2.919
ATP5F1 ATP synthase, H+ transporting, mitochondrial Fo
complex subunit B1
2.216
ATP5H ATP synthase, H+ transporting, mitochondrial Fo
complex subunit D
1.623
ATP5I ATP synthase, H+ transporting, mitochondrial Fo
complex subunit E
1.736
ATP5J ATP synthase, H+ transporting, mitochondrial Fo
complex subunit F6
1.673
ATP5J2 ATP synthase, H+ transporting, mitochondrial Fo
complex subunit F2
−2.37
ATP5L ATP synthase, H+ transporting, mitochondrial Fo
complex subunit G
−15.581
ATP5O ATP synthase, H+ transporting, mitochondrial F1
complex, O subunit
−601.813
COX4I1 Cytochrome c oxidase subunit 4I1 1.669
COX4I2 Cytochrome c oxidase subunit 4I2 −137.623
COX5A Cytochrome c oxidase subunit 5A 1.913
COX5B Cytochrome c oxidase subunit 5B 2.364
COX6B1 Cytochrome c oxidase subunit 6B1 1.87
COX6C Cytochrome c oxidase subunit 6C 2.38
COX7A2 Cytochrome c oxidase subunit 7A2 −12.37
COX7A2L Cytochrome c oxidase subunit 7A2 like 1.617
CYB5A Cytochrome b5 type A 1.802
CYC1 Cytochrome c1 16.811
CYCS Cytochrome c, somatic 1.821
MT-ATP6 ATP synthase F0 subunit 6 −280.464
MT-CO2 Cytochrome c oxidase subunit II 4.759
MT-ND1 NADH dehydrogenase, subunit 1 (complex I) 11.786
MT-ND2 Mitochondrially encoded NADH dehydrogenase 2 −7.366
MT-ND5 NADH dehydrogenase, subunit 5 (complex I) −8.753
NDUFA2 NADH:ubiquinone oxidoreductase subunit A2 1.51
NDUFA4 NDUFA4, mitochondrial complex associated 2.201
NDUFA5 NADH:ubiquinone oxidoreductase subunit A5 1.527
NDUFA6 NADH:ubiquinone oxidoreductase subunit A6 −112.999
NDUFA8 NADH:ubiquinone oxidoreductase subunit A8 45.057
NDUFA9 NADH:ubiquinone oxidoreductase subunit A9 3.523
NDUFA10 NADH:ubiquinone oxidoreductase subunit A10 10.495
NDUFA12 NADH:ubiquinone oxidoreductase subunit A12 −60.713
NDUFA13 NADH:ubiquinone oxidoreductase subunit A13 1.767
NDUFAB1 NADH:ubiquinone oxidoreductase subunit AB1 −3.356
NDUFB3 NADH:ubiquinone oxidoreductase subunit B3 1.558
NDUFB4 NADH:ubiquinone oxidoreductase subunit B4 2.211
NDUFB5 NADH:ubiquinone oxidoreductase subunit B5 −338.956
NDUFB6 NADH:ubiquinone oxidoreductase subunit B6 2.247
(Continued)
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TABLE 2 | Continued
Symbol Gene name Fold change
Oxidative phosphorylation
NDUFB7 NADH:ubiquinone oxidoreductase subunit B7 −20.943
NDUFB9 NADH:ubiquinone oxidoreductase subunit B9 2.454
NDUFB10 NADH:ubiquinone oxidoreductase subunit B10 1.609
NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1 −77.83
NDUFS2 NADH:ubiquinone oxidoreductase core subunit S2 −22.623
NDUFS3 NADH:ubiquinone oxidoreductase core subunit S3 −21.085
NDUFS5 NADH:ubiquinone oxidoreductase subunit S5 1.686
NDUFS6 NADH:ubiquinone oxidoreductase subunit S6 1.977
NDUFS7 NADH:ubiquinone oxidoreductase core subunit S7 −69.072
NDUFS8 NADH:ubiquinone oxidoreductase core subunit S8 −45.818
NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1 1.552
NDUFV2 NADH:ubiquinone oxidoreductase core subunit V2 −5.91
SDHA Succinate dehydrogenase complex flavoprotein
subunit A
1.617
SDHB Succinate dehydrogenase complex iron sulfur
subunit B
2.018
UQCR10 Ubiquinol-cytochrome c reductase, complex III
subunit X
2.354
UQCR11 Ubiquinol-cytochrome c reductase, complex III
subunit XI
1.501
UQCRB Ubiquinol-cytochrome c reductase binding protein 1.534
UQCRC1 Ubiquinol-cytochrome c reductase core protein I −4.993
UQCRC2 Ubiquinol-cytochrome c reductase core protein II 373.541
UQCRH Ubiquinol-cytochrome c reductase hinge protein −40.845
UQCRQ Ubiquinol-cytochrome c reductase complex III
subunit VII
9.76
Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-
regulated proteins; Green: Down-regulated proteins. Proteomics was performed as
described in Materials and Methods. Statistical analyses were performed using ANOVA
and 1.5-fold-changes in proteins with a p < 0.05 were considered. Dataset containing
proteins with significant altered expression profile were imported into the Ingenuity
Pathway Analyses (IPA) software, which groups the differentially expressed proteins into
known functions and pathways.
RESULTS
Cancer stem cells (CSCs) are characterized by elevated
mitochondrial biogenesis and metabolism (2). However,
mitochondrial function is also largely dependent on a
well-regulated balance between mitochondrial fusion and
fission dynamics (19, 23). In fact, aberrantly activated fission
results in mitochondrial fragmentation, which is associated to
mitochondrial dysfunction.
Here, we interrogated how unopposed mitochondrial fission
may promote alterations in mitochondrial biology and function,
leading to inhibition of CSCs propagation in breast cancer.
MFF Inhibits Mitochondrial Biogenesis
In order to investigate the role of MFF in the regulation of
mitochondrial activity in breast cancer cells, we generated an
isogenic MCF7 cell line harboring MFF (MCF7-MFF), together
with a matched isogenic cell line harboring the empty vector,
which served as a control (MCF7-Control). After verifying
TABLE 3 | Significant changes in protein levels associated with the tricarboxylic
acid cycle in MCF7 cells over-expressing mitochondrial fission factor (MFF).
Symbol Gene name Fold change
TCA cycle
ACO1 Aconitase 1 −33.921
ACO2 Aconitase 2 −14.648
CS Citrate synthase −34.112
DHTKD1 Dehydrogenase E1 and transketolase domain
containing 1
−3.207
DLD Dihydrolipoamide dehydrogenase 3.814
DLST Dihydrolipoamide S-succinyltransferase −3.202
FH Fumarate hydratase 14.079
IDH1 Isocitrate dehydrogenase [NADP(+)] 1, cytosolic 4.014
IDH2 Isocitrate dehydrogenase [NADP(+)] 2,
mitochondrial
−176.206
IDH3A Isocitrate dehydrogenase 3 [NAD(+)] alpha −17.146
IDH3B Isocitrate dehydrogenase 3 [NAD(+)] beta 1.752
IDH3G Isocitrate dehydrogenase 3 [NAD(+)] gamma 3.159
MDH1 Malate dehydrogenase 1 24.472
MDH2 Malate dehydrogenase 2 −211.122
OGDH Oxoglutarate dehydrogenase −47.17
OGDHL Oxoglutarate dehydrogenase-like 4.76
SDHA Succinate dehydrogenase complex flavoprotein
subunit A
1.617
SDHB Succinate dehydrogenase complex iron sulfur
subunit B
2.018
SUCLA2 Succinate-CoA ligase ADP-forming beta subunit 3.127
SUCLG1 Succinate-CoA ligase alpha subunit 6.425
Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-
regulated proteins; Green: Down-regulated proteins. Proteomics was performed as
described in Materials and Methods. Statistical analyses were performed using ANOVA
and 1.5-fold-changes in proteins with a p < 0.05 were considered. Dataset containing
proteins with significant altered expression profile were imported into the Ingenuity
Pathway Analyses (IPA) software, which groups the differentially expressed proteins into
known functions and pathways.
MFF-overexpression by Western blotting (Figure 1A), the newly
generated cell lines were subjected to functional phenotypic
characterization. As a first step, cells were analyzed by FACS
analysis using MitoTracker Deep-Red-FM, as a probe to estimate
mitochondrial mass. As shown in Figure 1C, mitochondrial
content was reduced by 30% in MCF7-MFF cells. A similar
trend was observed for the evaluation of mitochondrial activity
by FACS analysis, using the probe Mito-Orange (Figure 1B),
suggesting an overall impairment in mitochondrial content and
function in the presence of MFF-overexpression.
MFF Inhibits Breast Cancer Cell
Metabolism
Data shown above immediately suggest that MFF may
interfere with mitochondrial oxidative metabolism. To test
this hypothesis, we directly evaluated metabolic flux using the
Seahorse XFe96 and we found that Oxygen Consumption Rates
(OCR) were significantly reduced inMCF7-MFF cells (Figure 2).
More specifically, basal respiration and maximal respiration
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TABLE 4 | Significant changes in protein levels associated with glycolysis in MCF7
cells over-expressing mitochondrial fission factor (MFF).
Symbol Gene name Fold change
Glycolysis
GLUT1 Facilitated glucose transporter member 1 −27.22
HXK1 Hexokinase 1 −17.96
HXK2 Hexokinase 2 –Infinity
HXK3 Hexokinase 3 1.755
ALDOA Aldolase, fructose-bisphosphate A −63.01
ALDOC Aldolase, fructose-bisphosphate C 3.304
ENO1 Enolase 1 −353.572
ENO2 Enolase 2 −14.088
ENO3 Enolase 3 4.658
FBP1 Fructose-bisphosphatase 1 −5.137
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 37.238
GPI Glucose-6-phosphate isomerase 3.486
PFKM Phosphofructokinase, muscle −5.855
PFKP Phosphofructokinase, platelet –Infinity
PGAM1 Phosphoglycerate mutase 1 3.86
PGAM4 Phosphoglycerate mutase family member 4 1.668
PGK1 Phosphoglycerate kinase 1 250.959
PGK2 Phosphoglycerate kinase 2 −28.097
PKLR Pyruvate kinase, liver and RBC −11.843
PKM Pyruvate kinase, muscle −92.492
TPI1 Triosephosphate isomerase 1 −44.171
LDHA Lactate dehydrogenase A 2.82
LDHA6LB Lactate dehydrogenase A like 6B −58.176
Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-
regulated proteins; Green: Down-regulated proteins. Proteomics was performed as
described in Materials and Methods. Statistical analyses were performed using ANOVA
and 1.5-fold-changes in proteins with a p < 0.05 were considered. Dataset containing
proteins with significant altered expression profile were imported into the Ingenuity
Pathway Analyses (IPA) software, which groups the differentially expressed proteins into
known functions and pathways.
were reduced by nearly 40% (Figures 2B,E); accordingly, ATP
levels were also depleted (Figure 2D). Notably, the analysis
of Extracellular Acidification Rates (ECR) demonstrated that
also the glycolytic pathway is inhibited in MCF7-MFF cells
(Figure 3). In particular, a nearly 40 % decrease in glycolysis and
glycolytic capacity (Figures 3B,C) were observed; an inhibitory,
though not significant, trend was also observed for glycolytic
reserve and non-glycolytic acidification (Figures 3D,E). Taken
together, these data indicate that MFF over-expression negatively
affects the metabolic cell machinery, by interfering with both
oxidative phosphorylation and glycolysis in breast cancer cells.
MFF Inhibits Breast CSC Activity
We previously established that within the heterogeneous
tumor mass, cancer cells exhibiting stemness features are also
characterized by an elevated level of mitochondrial function
(5, 6, 28). On the other hand, strategies aimed at targeting
mitochondria have proven to be beneficial in halting CSCs,
both in pre-clinical and clinical studies (9, 12, 29, 30).
Based on these observations, we investigated whether aberrant
TABLE 5 | Significant changes in protein levels associated with the pentose
phosphate pathway in MCF7 cells overexpressing mitochondrial fission factor
(MFF).
Symbol Gene name Fold change
Pentose phosphate pathway
G6PD Glucose-6-phosphate dehydrogenase −136.908
PGD Phosphogluconate dehydrogenase 4.903
PGLS 6-phosphogluconolactonase 1.776
RPE Ribulose-5-phosphate-3-epimerase 2.25
RPIA Ribose 5-phosphate isomerase A −11.28
TALDO1 Transaldolase 1 −6.741
TKT Transketolase −82.993
Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-
regulated proteins; Green: Down-regulated proteins. Proteomics was performed as
described in Materials and Methods. Statistical analyses were performed using ANOVA
and 1.5-fold-changes in proteins with a p < 0.05 were considered. Dataset containing
proteins with significant altered expression profile were imported into the Ingenuity
Pathway Analyses (IPA) software, which groups the differentially expressed proteins into
known functions and pathways.
mitochondrial fission may affect CSC propagation, together with
the impairment of mitochondrial function. For this purpose,
we used the 3D tumor-sphere formation assay as readout for
CSCs activity. Figure 4A shows that mammosphere formation
is inhibited by nearly 50% in MCF7-MFF cells. Likewise, ALDH
activity, a surrogate marker of stemness, was reduced by >60%
inMCF7-MFF cells (Figures 4B,C). These results clearly indicate
that MFF over-expression hampers breast CSCs propagation.
Proteomic Profiling Reveals the
MFF-Dependent Metabolic, Signaling, and
Biological Landscape
Dysfunctional mitochondria activate a retrograde signaling
network that shapes the nuclear transcriptomic program toward
the regulation of cell morphology and function, for cells to
response to disruption of energy metabolism (31). Adding to this,
several lines of evidence indicate that mitochondrial dynamics
might be involved in the regulation of stress signaling (14).
Hence, we sought to depict the metabolic and signaling network
landscape of MFF over-expressing breast cancer cells by using an
“omics” approach.More specifically, unbiased proteomic analysis
was performed in MCF7-MFF as well as in the matched MCF7-
Control counterpart. Thereafter, the software Ingenuity Pathway
was used to: (i) classify and group the proteins differentially
regulated in response to MFF overexpression; (ii) predict how
the upstream regulators may cause downstream phenotypic or
functional changes in response to MFF overexpression.
Metabolomic Signature
Results, shown in Tables 1–5, indicate that increased expression
of MFF fosters a transition toward a metabolically quiescent cell
phenotype. In particular, proteins involved in mitochondrial
biogenesis (Table 1), Oxidative Phosphorylation (Table 2) and
TCA cycle (Table 3) are the most strongly down-regulated in
MCF7-MFF, as compared to MCF-Control cells. Furthermore,
Frontiers in Oncology | www.frontiersin.org 9 October 2020 | Volume 10 | Article 1776
Sánchez-Alvarez et al. MFF Reduces CSCs Activity
FIGURE 5 | Precursors of metabolism list. Precursor of metabolism list enriched by the proteins significantly regulated in MCF7 harboring mitochondrial fission factor
(MFF) compared to MCF7 Control cells. The list has been generated by Ingenuity Pathway Analysis (IPA). The p-value for each pathway is represented by the height of
the bars and is expressed as −1 times the log of the p-value. The orange dotted line represents the threshold of p = 0.05 as calculated by Fischer’s test and denotes
the cut-off for significance.
inhibition of proteins involved in the glycolytic and the pentose
phosphate pathways is observed in MCF7-MFF cells (Tables 4,
5). Likewise, a higher accumulation of proteins involved in
the metabolism of metabolic precursors mainly for Oxidative
phosphorylation, TCA cycle and Glycolysis is detected in
MCF7-MFF cells, suggesting that the metabolic machinery
is inhibited in the presence of enhanced mitochondrial
fragmentation (Figure 5). Also, it appears that MFF over-
expression triggers the up-regulation of a “toxicity network”
of proteins, mainly related to cell metabolism (Figure 6).
The most strongly up-regulated “toxicity” proteins are
classified as regulators of mitochondrial dysfunction, together
with oxidative stress response and fatty acid metabolism
(Figure 6). Also, a “toxicity network” of proteins involved in the
regulation of mitochondrial membrane potential and hypoxia
signaling are engaged as relevant effectors in MCF7-MFF cells
(Figure 6).
Signaling Pathways and Predicted
Biological Responses
To interrogate how MFF over-expression would trigger the
activation of specific intracellular signaling cascades, which are
predicted to control distinct biological responses, a dataset
containing proteins with significant altered expression profile
was imported into the IPA tool. As shown in Figure 7, the most
strongly differentially activated pathways in MCF7-MFF cells
are predicted to regulate EI2F signaling, as well as epithelial
adherens junctions and the cytoskeleton. Accordingly, down-
regulation of proteins involved in Epithelial Mesenchymal
Transition (EMT), Extracellular Matrix (ECM) and cytoskeleton
remodeling is detected in MCF-MFF cells (Table 6). In
addition, proteins involved in metastasis formation (MTA1
and MTA2), oxidative stress signaling (CAT, SOD2, TXNRD1,
GLRX3, GSR, TXNL1, TXNRD2, TXNRD3), TGFß pathway
(TGFB1, TGFBR3, TGFIF2lX, STAT1, STAT3) and TNF-alpha
(TNFRSF12A, TRAF2) were all dramatically down-regulated
in MCF7-MFF cells (Table 7). In order to further characterize
the signaling landscape of MCF7-MFF cells, we performed
a Regulator-Effects analysis, which integrates and merges
together Upstream Regulator Networks with Downstream Effect
Networks, thereby deriving how predicted regulators might
impact biological processes. As shown in Figure 8, inhibition
of cell adhesion and survival (A), and activation of cell death
response (B) are the main biological events associated with MFF
over-expression. The identification of the signaling mediators
potentially linking upstream mediators with down-stream effects
is also shown. Taken together, these data suggest that aberrant
mitochondrial fragmentation may halt breast cancer cell survival
and activate cell death programs by regulating a number of
effectors also involved in ECM remodeling, the oxidative stress
response, and mitochondrial metabolic function.
Frontiers in Oncology | www.frontiersin.org 10 October 2020 | Volume 10 | Article 1776
Sánchez-Alvarez et al. MFF Reduces CSCs Activity
FIGURE 6 | Toxicological Pathways and Functions significantly regulated in MCF7 cells overexpressing the mitochondrial fission factor (MFF). Toxicity list enriched by
the proteins significantly regulated in MCF7 harboring mitochondrial fission factor (MFF) has been generated by Ingenuity Pathway Analysis (IPA). The p-value for each
pathway is represented by the height of the bars and is expressed as −1 times the log of the p-value. The orange dotted line represents the threshold of p = 0.05 as
calculated by Fischer’s test and denotes the cut-off for significance.
DISCUSSION
Here, we have generated a mitochondrial fission factor (MFF)-
overexpressing breast cancer cell line in order to dissect the
role of aberrant mitochondrial fission in the maintenance
and dissemination of breast CSCs. We have found that
MFF overexpression inhibits mitochondrial biogenesis and
oxidative metabolism, depleting intracellular ATP levels.
Furthermore, MFF-overexpressing breast cancer cells exhibit
a reduction in stemness properties, as evidenced by the
inhibition of 3D mammosphere formation capacity and
decreases in the stem cell marker ALDH. Consistent with
these observations, proteomic analysis performed in MFF-
overexpressing breast cancer cells predicted a proteomic
signature associated with the inhibition of mitochondrial
function, and a metabolically quiescent cell phenotype, as well
as the inhibition of cancer cell survival and the increase of
cell death.
Mitochondria, which have classically been considered
as the cell’s “power-house,” extract energy from oxidative
phosphorylation to efficiently support tumor growth (1).
Despite their unquestionable role in generating ATP from
multiple fuels, mitochondria are now considered as central
hubs which drive important tumor traits. For instance,
mitochondria have been implicated in metastasis formation
and spreading to distant sites, as well as drug resistance (18).
In addition, mitochondria have been shown to support the
survival of dormant tumor cells after oncogene ablation,
thus promoting disease relapse (32). Many of these actions
attributed to mitochondria have been correlated with the
impact that these organelles exert on the biology of CSCs (33).
Several lines of evidence have suggested that mitochondria
support stem cell traits, thus facilitating self-renewal and
resistance to differentiation (2). For instance, a strict reliance on
young, viable and competent mitochondria is required during
asymmetric cell division; in fact, older and aged mitochondria
are clustered within daughter cells committed to differentiation,
whereas “newly synthesized” and younger mitochondria are
apportioned within daughter cells that retain a stem-like
phenotype (34).
As the relationship between the mitochondrial-dependent
bioenergetic responses and the CSC metabolic profile has
been explored, it’s not surprising that a mitochondria-
centric regulation of cancer energy pathways can drive
complex decision-making events, ultimately impacting
CSC fate toward tumor progression. As a consequence
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FIGURE 7 | Canonical pathways enriched in proteins differentially regulated in MCF7 cells overexpressing the mitochondrial fission factor (MFF). Significant canonical
pathways associated to cell signaling were generated by Ingenuity Pathway Analysis (IPA). X axis represents pathways and Y axis represents –log (p-value) calculated
with Fisher’s exact test. A p-value threshold of 0.05 is applied and is represented by the orange dotted line.
of these findings, synthetic as well as natural compounds
that impair mitochondrial function have been shown to
selectively hamper CSC propagation in diverse tumor types
(30, 35–38). Interestingly, as mitochondria evolutionary
derive from the engulfment of an α-proteobacterium in
eukaryotic host cells, several classes of FDA-approved
antibiotics have been suggested in a repurposing effort for
the selective targeting of mitochondria (12, 39). The most
remarkable of these repurposing strategies is represented
by the antibiotic Doxycycline, a relatively manageable and
safe tetracycline analog, which inhibits CSC dissemination
in vitro, by targeting mitochondria biogenesis, as well as
mitochondrial-dependent bioenergetic metabolism (11). Of
note, a Phase II clinical trial performed in early breast cancer
patients, using the oral administration of Doxycycline, was
sufficient to selective reduce the stemness markers ALDH1 and
CD44 (9). These studies pave the way for further exploring
the role of mitochondria in cancer, and the investigation of
novel mitochondrial-based druggable targets to be exploited as
anti-cancer strategies.
Mitochondrial fission and fusion dynamics play an
integral role in the complex regulation of mitochondrial
function (25). Fragmentation and fusion are tightly
balanced processes which probably derive from the same
endowment mechanisms through which bacteria were
co-opted into host cells. As such, it’s not surprising that
alterations in fusion/fission balance may play a key role
in the pathogenesis of several diseases, including cancer
(16, 25).
Our data show that in breast cancer enhanced mitochondrial
fragmentation reduces mitochondrial mass and membrane
potential, suggesting that aberrant fission may compromise
the efficiency of the energetic cell machinery. Mechanistically,
this model could be explained by the bi-directional link
existing between mitochondrial morphology and redox
homeostasis. In fact, pro-fission programs leading to
mitochondrial fragmentation have been shown to stimulate
ROS production (40); furthermore, the activation of
mitochondrial fission was required to generate ROS during
hyperglycemic conditions (41), thereby suggesting that
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TABLE 6 | Significant changes in protein levels associated with the
epithelial-mesenchymal transition (EMT), extracellular matrix and cytoskeleton in
MCF7 cells over-expressing mitochondrial fission factor (MFF).
Symbol Gene name Fold change
Epithelial-mesenchymal transition, ECM and cytoskeleton proteins
VIM Vimentin −122.836
ACTA2 Actin, alpha 2, smooth muscle, aorta −1.639
TNC Tenascin C −18.294
CNN2 Calponin 2 109.554
CALU Calumenin 9.943
CAND1 Cullin associated and neddylation dissociated 1 −50.592
CANX Calnexin 289.77
CFL1 Cofilin 1 −4.993
CTNNA1 Catenin alpha 1 15.851
CTNNA2 Catenin alpha 2 −46.852
CTNND1 Catenin delta 1 −50.914
GSN Gelsolin −9.378
KTN1 Kinectin 1 −27.16
VCL Vinculin 2.965
THBS1 Thrombospondin 1 −26.041
TAGLN2 Transgelin 2 3.578
TAGLN3 Transgelin 3 −18.464
CUL1 Cullin 1 −24.7
CUL2 Cullin 2 −3.6
CUL3 Cullin 3 −43.342
CUL7 Cullin 7 −24.685
CUL4A Cullin 4A −4.282
CUL4B Cullin 4B −30.196
DES Desmin −2.734
COL11A1 Collagen type XI alpha 1 chain −156.421
COL28A1 Collagen type XXVIII alpha 1 chain −65.077
COL2A1 Collagen type II alpha 1 chain −110.781
COL8A1 Collagen type VIII alpha 1 −7.542
ACTB Actin beta −378.155
ACTBL2 Actin, beta like 2 −100.94
ACTC1 Actin, alpha, cardiac muscle 1 −101.765
ACTG1 Actin gamma 1 4.483
ACTN1 Actinin alpha 1 −4.133
ACTN2 Actinin alpha 2 −2.295
ACT Actin-like protein (ACT) gene −20.682
ACTG1P4 Actin gamma 1 pseudogene 4 −2.329
ACTN4 Actinin alpha 4 30.372
MYH9 Myosin, heavy chain 9, non-muscle 820.527
MYH10 Myosin, heavy chain 10, non-muscle 7.969
MYH11 Myosin heavy chain 11 −46.952
MYH7B Myosin heavy chain 7B −13.017
MYL1 Myosin light chain 1 −10.816
MYL6 Myosin light chain 6 1.94
MYL12A Myosin light chain 12A 2.173
MYL6B Myosin light chain 6B –Infinity
MYO1B Myosin IB 1.551
MYO1C Myosin IC −51.931
TUBA8 Tubulin alpha 8 −15.245
(Continued)
TABLE 6 | Continued
Symbol Gene name Fold change
Epithelial-mesenchymal transition, ECM and cytoskeleton proteins
TUBA1A Tubulin alpha 1a 1.545
TUBA3E Tubulin alpha 3e 1.5
TUBA4A Tubulin alpha 4a −22.152
TUBAL3 Tubulin alpha like 3 −3.393
TUBB3 Tubulin beta 3 class III −3.965
TUBB6 Tubulin beta 6 class V −18.369
TUBB8 Tubulin beta 8 class VIII 1.78
TUBB2A Tubulin beta 2A class IIa −2.783
TUBB2B Tubulin beta 2B class IIb 2.353
TUBB4A Tubulin beta 4A class IVa 2.216
TUBGCP2 Tubulin gamma complex associated protein 2 –Infinity
TUBGCP6 Tubulin gamma complex associated protein 6 –Infinity
TUBA1B Tubulin alpha 1b −5.529
TUBA1C Tubulin alpha 1c −11.125
TUBB Tubulin beta class I −90.993
TUBB4B Tubulin beta 4B class IVb −25.109
DNM1 Dynamin 1 −20.927
DNM2 Dynamin 2 −18.654
DNM3 Dynamin 3 −9.012
DNMBP Dynamin binding protein −4.552
LAMA3 Laminin subunit alpha 3 −58.838
LAMB2 Laminin subunit beta 2 −12.831
LAMB3 Laminin subunit beta 3 −77.639
LAMB4 Laminin subunit beta 4 −8.215
Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-
regulated proteins; Green: Down-regulated proteins. Proteomics was performed as
described in Materials and Methods. Statistical analyses were performed using ANOVA
and 1.5-fold-changes in proteins with a p < 0.05 were considered. Dataset containing
proteins with significant altered expression profile were imported into the Ingenuity
Pathway Analyses (IPA) software, which groups the differentially expressed proteins into
known functions and pathways.
unopposed mitochondrial fragmentation is associated
with enhanced ROS production and compromission of the
energetic machinery.
Indeed, analysis of metabolic flux showed that in MFF-
overexpressing breast cancer cells the capability to extract
ATP from energetic sources is compromised. These data are
in accordance with previous studies showing that natural or
synthetic compounds that block mitochondrial biogenesis
and thereby reduce mitochondrial mass, also interfere with
mitochondrial energetic function [reviewed in (8)]. Likewise,
the metabolic effects of abnormal mitochondrial fission
may parallel the biochemical responses observed in breast
cancer cells treated with mitochondrial-targeting agents.
Our data from proteomic analyses provide supporting
evidence that MFF over-expression mainly drives the
acquisition of a metabolically suppressed cell phenotype,
as demonstrated by the drastic reduction of proteins
involved in several energetic pathways in MCF7-MFF vs.
Frontiers in Oncology | www.frontiersin.org 13 October 2020 | Volume 10 | Article 1776
Sánchez-Alvarez et al. MFF Reduces CSCs Activity
TABLE 7 | Significant changes in other protein levels in MCF7 cells
over-expressing mitochondrial fission factor (MFF).
Symbol Gene name Fold change
Other proteins
MTA1 Metastasis associated 1 −41.671
MTA2 Metastasis associated 1 family member 2 −17.064
MTSS1L Metastasis suppressor 1 like 2.028
UCP3 Uncoupling protein 3 −62.533
TIGAR TP53 induced glycolysis regulatory phosphatase −39.761
TGFBI Transforming growth factor beta induced –Infinity
TGFBR3 Transforming growth factor beta receptor 3 −8.57
TGIF2LX TGFB induced factor homeobox 2 like, X-linked −12.818
STAT1 Signal transducer and activator of transcription 1 −9.228
STAT3 Signal transducer and activator of transcription 3 −7.953
OXSR1 Oxidative stress responsive 1 6.331
PCNA Proliferating cell nuclear antigen 3.128
HSF1 Heat shock transcription factor 1 −28.884
TRAP1 TNF receptor associated protein 1 −10.989
CAT Catalase −10.918
SOD2 Superoxide dismutase 2, mitochondrial −33.389
TXNRD1 Thioredoxin reductase 1 −21.824
GLRX3 Glutaredoxin 3 −1.845
GSR Glutathione-disulfide reductase −1E+08
GSS Glutathione synthetase 2.547
GSTM3 Glutathione S-transferase mu 3 18.065
ROMO1 Reactive oxygen species modulator 1 1.966
SMAD9 SMAD family member 9 −1.975
TXNL1 Thioredoxin like 1 −9.869
TXNRD2 Thioredoxin reductase 2 −3.538
TXNRD3 Thioredoxin reductase 3 –Infinity
TMX1 Thioredoxin related transmembrane protein 1 3.142
TMX4 Thioredoxin related transmembrane protein 4 1.518
TNFRSF12A TNF receptor superfamily member 12A –Infinity
TNFSF13B Tumor necrosis factor superfamily member 13b 2.397
TRAF2 TNF receptor associated factor 2 −7.759
Fold change of proteins detected in MCF7-MFF vs. MCF7-Control cells. Red: Up-
regulated proteins; Green: Down-regulated proteins. Note down-regulation of relevant
proteins involved in themetastatic process and oxidative stress response. Proteomics was
performed as described in Materials and Methods. Statistical analyses were performed
using ANOVA and 1.5-fold-changes in proteins with a p < 0.05 were considered. Dataset
containing proteins with significant altered expression profile were imported into the
Ingenuity Pathway Analyses (IPA) software, which groups the differentially expressed
proteins into known functions and pathways.
MCF7-Control cells. Therefore, unopposed mitochondrial
fragmentation induces mitochondrial dysfunction, leading to
the inability to extract ATP from fuels and an overall block in
cell metabolism.
As cancer cells are strictly dependent on active energetic
cellular machinery for their survival, any alteration in
mitochondrial integrity may compromise cancer cell
viability (42, 43). The proteomic analyses performed in
MFF-overexpressing breast cancer cells showed that enhanced
mitochondrial fission is associated not only with loss of
mitochondrial proteins, impaired ability to cope with
oxidative stress, and reduced metabolic function, but also
with a quiescent cell phenotype. More specifically, the
proteomic landscape of MFF over-expressing breast cancer
cells highlights a clear inhibition of proteins involved in
cell adhesion and cell junction, together with the inhibition
of the EMT program, and metastasis-related mediators.
Furthermore, our proteomic analysis predicts a substantial
inhibition of cell survival pathways and the activation of cell
death programs, consistent with a metabolically suppressed
cell phenotype.
These data are in accordance with previous studies
showing that MFF-dependent mitochondrial fission
activates signaling pathways involved in the inhibition of
cell viability and the activation of the apoptotic response
(44). In particular, MFF and other mediators involved in
mitochondrial fragmentation such as DRP1 play an integral
role in cancer cell death in response to diverse stimuli,
including several anticancer drugs (45, 46). At least some
of these effects could be attributed to the generation of
mitochondrial ROS, which would thereafter trigger apoptotic
cell death (47).
Mitochondrial proteins are overexpressed in CSCs, which
also exhibit increased mitochondrial metabolic function
(2, 5, 7). Indeed, tracking mitochondrial mass represents
an important metabolic tool to identify an enrichment of
CSCs (7). Due to these unusual features, CSCs are selectively
targeted by a number of mitochondria impairing agents, which
have been shown to compromise mitochondrial function
and thereafter halt CSC propagation (8). Likewise, in the
present study we have shown that mitochondrial-driven
impairment in metabolic function is associated with the
loss of stemness features in MFF over-expressing breast
cancer cells. These observations indicate that uncontrolled
mitochondrial fission may drive the acquisition of an
inactive metabolic phenotype associated with the starvation
of the CSCs population. Therefore, the pharmacological
manipulation of mitochondrial fission may serve as an
actionable tool to eradicate cancer cells, with tumor initiating
capabilities. Accordingly, it has been recently shown that
an MFF peptidomimetic strategy elicits anti-cancer activity
in patient-derived xenografts, primary breast and lung
adenocarcinoma 3D organoids, as well as glioblastoma
neurospheres (45).
Recently, drugs targeting mitochondrial dynamics are
beginning to emerge as novel strategies in cancer treatment.
It should be mentioned that their potential is still challenged
by several controversies and awaits further confirmation.
For instance, the inhibitor of mitochondrial fission named
mdiv-1, which acts as a Drp1 GTPase activity inhibitor,
can cause a loss of the functional properties of CSCs (48).
However, this drug appears to also work as a reversible
inhibitor of mitochondrial complex I, leading to alterations
of mitochondrial ROS production (49). Additional layers
of complexity have to be considered when exploring the
contribution of mitochondrial shaping genes in tumor
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FIGURE 8 | Regulator effect networks generated by Ingenuity Pathway Analysis (IPA) in MCF7 over-expressed mitochondrial fission factor (MFF). IPA analysis
generated several regulator effect networks in MCF7 cells over-expressing mitochondrial fission factor (MFF). Both upstream regulators and downstream cellular
responses were identified in relation to certain proteins significantly altered in our dataset. Upstream regulators are shown at the top while functions and phenotypes
are displayed at the bottom. Significantly regulated proteins connecting the upper and lower panel are displayed in the middle. Red and green colors represent
significant up/down-regulation, respectively, with the intensity of the color reflecting the degree of change. Orange color predicts an overall activation of the pathway
while blue indicates a prediction of an overall decrease based on z-score value. Inconsistent relationships are represented as yellow line. Note that in MCF7 harboring
MFF some of the proteins in our dataset have been predicted to be inhibited by the upstream regulators ERG, LGALS3, and MYC leading to an overall inhibition (blue)
of cell survival and/or activation (orange) of cell death. (A) Cell survival and adhesion; (B) Cell death.
biology. Indeed, tumor microevironmental conditions;
the presence of hormonal/growth factors; and intrinsic
features of the specific tumor cell types involved may affect
mitodynamics pathways.
In conclusion, the data presented herein validate the
use of a mitodynamic approach to target mitochondria
architecture and function toward the eradication of CSCs.
Further studies will be necessary to validate the use of this
therapeutic strategy, especially in combination with additional
metabolic inhibitors as novel tools to control stem traits
in cancer.
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